A new clinical study identified withanolide glycosides as the key drivers of superior bioavailability in ashwagandha (Withania somnifera) extracts.
This marks the first direct evidence in humans that the type of withanolide — not just the total content — significantly influences absorption and efficacy.
Shoden ashwagandha extract, the innovation of nutraceutical pioneers Arjuna Natural, demonstrated superior performance in uptake in the volunteer subjects.
The randomised, open-label, crossover clinical study, led by Priyank Rathi, MD, was published in the journal Current Therapeutic Research.
It evaluated the bioavailability in 16 healthy human volunteers of four commercially available, standardised ashwagandha extracts with varying compositions, including Shoden standardised to 35% Withania somnifera withanolide glycosides (WS-35), 10% (WS-10), 5% (WS-5) or 2.5% (WS-2.5).
Each sample was standardised to deliver 185 mg of total withanolides. Seventeen blood samples were collected during a 24-hour period after dosing.
Plasma concentrations of withanolide A, withanoside IV, withaferin A and total withanolides were quantified, and pharmacokinetic parameters — how the body metabolises a substance with time — were calculated.
Results of the study revealed striking differences in their pharmacokinetic profiles.
Extracts rich in withanolide glycosides — particularly those derived from the plant — demonstrated markedly higher systemic exposure. With Shoden in the lead, these extracts showed longer half-lives, indicating prolonged circulation of active compounds in the body.
New gold standard
“Clinical data now confirm that withanolide glycosides stand out not just for quantity but for quality, with higher bioavailable than other withanolide types,” reveals Benny Antony, PhD, Joint Managing Director of Arjuna Natural.
“Our findings suggest that the strength of ashwagandha is in its withanolide profile, specifically the chemical nature of the withanolides — and not their total amount."
"This plays a critical role in determining the uptake and metabolism of ashwagandha extracts in the body for optimal effect. This study emphasized the importance of extract composition and the plant parts used.”
Shoden is a highly bioactive extract of ashwagandha, with an industry leading 35% withanolide glycosides, the key active compounds in the plant.
Derived from carefully chosen and validated ashwagandha sources, Arjuna employs a proprietary extraction process to deliver a potent holistic charge of the popular adaptogenic, even at a uniquely low dose of 60 mg.
This study marks the latest milestone in Arjuna’s robust collection of 12 clinical studies of Shoden. They showcase Shoden’s positive role in relieving stress and anxiety and improving sleep quality.
Research indicates its mechanisms of action include the ability to regulate the hypothalamus-pituitary-adrenal axis, reducing the stress hormone cortisol and increasing relaxing GABA neurotransmitters.
One clinical study highlighting its immunomodulating benefits revealed natural improvements in immune cell markers ... and toxicity studies have endorsed its safety.
Shoden outperformed other dominant formulations
“These findings have major implications for both consumers and supplement manufacturers. As ashwagandha continues to gain popularity for its adaptogenic, cognitive and stress-relieving benefits, the current research underscores the need for more detailed labelling and standardisation that goes beyond total withanolide content."
"Future clinical studies and product formulations should consider the specific withanolide profile — particularly the presence of glycosides — to deliver ashwagandha extracts with maximum efficacy and consistency,” concludes Antony.
Shoden has been internationally recognised for the 23 patents attributed to its unique formulation and manufacturing process.
It is available in three doses and in various supplement formats, including pills, capsules and powders. Its low-dose capabilities allow for seamless integration into functional foods and beverages.
